Clinical trials: Idiopathic Parkinsons Disease
Parkinson's Disease
The Practical Effect of Neupro
This is a multicenter, prospective, non intervention post marketing surveillance study conducted in Chinese mainland. The main objective was to evaluate the safety characteristics of rotigotine patch in the treatment of Chinese…
- Trial name
- NCT04957420
- Testing
- Neupro
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking University Third Hospital
Idiopathic Parkinson's Disease
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- SPAN-PD™ (NCT02240030)
- Testing
- CVT-301 Low Dose, CVT-301 High Dose
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 351 people
- Sponsor
- Acorda Therapeutics
Idiopathic Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
To evaluate the safety and efficacy of two dose ranges of safinamide (High Dose: 150 to 200 mg/day and Low Dose: 50 to 100 mg/day) orally, as compared to Placebo, as add-on therapy in patients with early idiopathic Parkinson's…
- Trial name
- NCT00643045
- Testing
- Safinamide
- Volunteers
- 269 people
- Sponsor
- Newron Pharmaceuticals SPA
Idiopathic Parkinson's Disease, Parkinson Disease
Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation
This study evaluates the effect of transcranial direct current stimulation (tDCS) on non-motor symptoms of Parkinson's disease, including depression and cognitive symptoms.
- Conditions
- Idiopathic Parkinson's Disease, Parkinson Disease, Depression
- Trial name
- NCT03074812
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Johns Hopkins University
Parkinson Disease
A Longitudinal Evaluation of Oculometric Measures and Clinical Assessment Over Time in PD Patients
This is a prospective study in a cohort of about 30 patients with Idiopathic Parkinson's disease, who will be evaluated with a clinical assessment and an oculometric examination during a time period with specific intervals.
- Trial name
- NCT05795023
- Testing
- NeuraLight
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- NeuraLight
Parkinson Disease
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period…
- Trial name
- PALOMA (NCT05862649)
- Testing
- NeuraLight
- Where
- 5 sites in United States, Portugal and 3 more
- Volunteers
- 300 people
- Sponsor
- NeuraLight
Idiopathic Parkinson Disease
A Study to Evaluate in Patients With Parkinsonian Type Disorders
A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders
- Trial name
- NCT03683225
- Testing
- CTC-413
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Chase Therapeutics Corporation
Parkinson Disease, Idiopathic, REM Sleep Behavior Disorder
Parkinson's Disease Biomarker Study
The primary objective of this study is to determine whether data acquired from a remote monitoring approach can reliably identify and track motor symptoms in prodromal PD and clinical PD.
- Trial name
- PDBS (NCT06812702)
- Testing
- Observational, Skin Biopsy
- Where
- 4 sites in Canada
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Ronald Postuma
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT01028586)
- Testing
- Safinamide, MAO-B inhibitor
- Where
- Switzerland
- Volunteers
- 507 people
- Sponsor
- Newron Pharmaceuticals SPA
Levodopa-induced Dyskinesia
Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia
The purpose of this study is to determine the safety, tolerability, pharmacokinetic and pharmacodynamic effects of single doses of Neu-120 in Parkinson's disease patients with levodopa-induced dyskinesia.
- Trial name
- NCT00607451
- Testing
- Neu-120
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Idiopathic Parkinson's Disease (PD)
Association of VAgus Nerve Stimulation and Treadmill Training for GAit Rehabilitation in DE Novo Parkinson's Disease
The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) can improve gait and brain function in people with diagnosis of idiopathic Parkinson's disease (PD) within 6 months.
- Trial name
- AVANTGARDE-PD (NCT07337226)
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Conventional Physical Therapy (cPT), Sensorized Treadmill Training (STT)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Idiopathic Parkinson's Disease
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
- Trial name
- NCT00985517
- Testing
- CERE-120: Adeno-Associated Virus Delivery of Neurturin
- Where
- 11 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sangamo Therapeutics
Depressive Symptoms, Parkinson's Disease
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total…
- Trial name
- ACCORDO (NCT01055379)
- Testing
- Rasagiline
- Where
- 12 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Lundbeck Italia S.p.A.
Parkinson's Disease
Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease
The primary objectives of the trial are to assess the safety and efficacy of ProSavin. Patients in the trial will have been diagnosed with Parkinson's disease and will be failing on current treatment with L-DOPA but they will not…
- Trial name
- NCT00627588
- Testing
- ProSavin
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Oxford BioMedica
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson´s Disease
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
The aim of this phase Ila trial is to provide evidence on safety, tolerability and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with early Parkinson's disease (PD).
- Trial name
- NCT05931575
- Testing
- Fasudil hydrochloride
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Technical University of Munich
Idiopathic Parkinson's Disease
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- NCT01777555
- Testing
- CVT-301
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 89 people
- Sponsor
- Acorda Therapeutics
Movement Disorders, Neurology
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years.
- Conditions
- Movement Disorders, Neurology, Parkinsons Disease
- Trial name
- NCT05539196
- Testing
- Exablate Pallidotomy, Unilateral
- Where
- 5 sites in United States, Japan
- Volunteers
- 60 people
- Sponsor
- InSightec
Parkinson Disease, Idiopathic
SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease
This study aims to evaluate whether wearable technology can improve the management of motor symptoms in people with Parkinson's disease (PD) who experience motor fluctuations throughout the day.
- Trial name
- SMART PD (NCT07066163)
- Testing
- Kinesia U, Standard of care treatment
- Where
- 2 sites in Canada
- Volunteers
- 32 people
- Sponsor
- Western University
Parkinson Disease, Idiopathic
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
Male and female patients aged ≥ 30 years with advanced stage idiopathic Parkinson's disease, not well controlled on existing levodopa will take part in a research study at approximately 82 sites in Europe, Israel, South Africa…
- Trial name
- NCT00244387
- Testing
- SPM 962
- Where
- Germany
- Volunteers
- 506 people
- Sponsor
- UCB Pharma